Hemispherx BioPharma, Inc.
17 Dec 2014
Available for Immediate Download
Hemispherx BioPharma, Inc. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Hemispherx BioPharma, Inc. required for business and competitor intelligence needs - Intelligence on Hemispherx BioPharma, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Hemispherx BioPharma, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Hemispherx BioPharma (Hemispherx) is a specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune based chronic disorders. Hemispherx's products include Alferon N Injection, Ampligen and Alferon LDO (Low Dose Oral). Hemispherx operates in the US and Belgium. It is headquartered in Philadelphia, Pennsylvania and employs around 39 people. The company recorded revenues of $150 thousand in the fiscal year ended December 2013, a decrease of 29.6% compared to 2012. The company's operating loss was $17,167 thousand in fiscal 2013, as compared to an operating loss of $20,340 thousand in 2012. Its net loss was $16,225 thousand in fiscal 2013, as compared to the net loss of $17,354 thousand in 2012. Reasons to Purchase: - Gain understanding of Hemispherx BioPharma, Inc. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Hemispherx BioPharma, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Hemispherx BioPharma, Inc. your competitors' business structure, strategy and prospects